Aerovate Therapeutics Inc

Research Aerovate Therapeutics Inc (JBIO) on Bullrun: market cap USD 1.09B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerJBIO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.09B
• Financial periodFY2025
• Net income-USD 127.41M
• Free cash flow-USD 94.89M

Valuation Snapshot

latest market cap is USD 1.09B.

About Aerovate Therapeutics Inc

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc.

Frequently asked questions

What is Aerovate Therapeutics Inc's market cap?

Aerovate Therapeutics Inc's market capitalization is USD 1.09B.

What does Aerovate Therapeutics Inc do?

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.